

NCT02068365 Raw comparison:

Summary:
CHIA has 33 criteria while your personal folder has 35 criteria
Total found criteria: 33/33
Total not Found: 0/33
Total Extra: 2
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Male & female patients >= 18 and < 70 years of age │ Male \& female patients \>= 18 and \< 70 years of  │
│                                                    │ age                                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Positive HBeAg before starting NA treatment        │ Positive HBeAg before starting NA treatment        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Treated by a single NA (lamivudine adefovir        │ Treated by a single NA (lamivudine adefovir        │
│ entecavir or tenofovir) for 6 months to 5 years    │ entecavir or tenofovir) for 6 months to 5 years    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Developed HBeAg seroconversion (HBeAg negative and │ Developed HBeAg seroconversion (HBeAg negative and │
│ ant-HBe negative) with undetectable HBV DNA by PCR │ ant-HBe negative) with undetectable HBV DNA by PCR │
│ based assay on NA treatment                        │ based assay on NA treatment                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Negative urine or serum pregnancy test (for women  │ Negative urine or serum pregnancy test (for women  │
│ of childbearing potential) documented within the   │ of childbearing potential) documented within the   │
│ 24-hour period prior to the first dose of test     │ 24-hour period prior to the first dose of test     │
│ drug Additionally all females must be using        │ drug Additionally all females must be using        │
│ reliable contraception during the study and for 3  │ reliable contraception during the study and for 3  │
│ months after treatment completion                  │ months after treatment completion                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Evidence of decompensated liver disease (Childs    │ Evidence of decompensated liver disease (Childs    │
│ B-C) hepato-cellular carcinoma pre-existing severe │ B-C) hepato-cellular carcinoma pre-existing severe │
│ depression or other psychiatric disease            │ depression or other psychiatric disease            │
│ significant cardiac disease significant renal      │ significant cardiac disease significant renal      │
│ disease seizure disorders or severe retinopathy    │ disease seizure disorders or severe retinopathy    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ received telbivudine as the antiviral therapy or   │ received telbivudine as the antiviral therapy or   │
│ have received more than one NA in the past         │ have received more than one NA in the past         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ received interferon or peginterferon treatment in  │ received interferon or peginterferon treatment in  │
│ the past                                           │ the past                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ received antiviral therapy for any systemic anti-  │ received antiviral therapy for any systemic anti-  │
│ viral anti-neoplastic or immuno-modulatory         │ viral anti-neoplastic or immuno-modulatory         │
│ treatment (including supraphysiologic doses of     │ treatment (including supraphysiologic doses of     │
│ steroids and radiation) within the past 6 months   │ steroids and radiation) within the past 6 months   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Positive test at screening for anti-HIV anti-HCV   │ Positive test at screening for anti-HIV anti-HCV   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients who are expected to need systemic         │ Patients who are expected to need systemic         │
│ antiviral therapy other than that provided by the  │ antiviral therapy other than that provided by the  │
│ study at any time during their participation in    │ study at any time during their participation in    │
│ the study are also excluded Exception patients who │ the study are also excluded Exception patients who │
│ have had a limited (<=7 days) course of acyclovir  │ have had a limited (\<=7 days) course of acyclovir │
│ for herpetic lesions more than 1 month prior to    │ for herpetic lesions more than 1 month prior to    │
│ the first administration of test drug are not      │ the first administration of test drug are not      │
│ excluded                                           │ excluded                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum total bilirubin > 3 times the upper limit of │ Serum total bilirubin \> 3 times the upper limit   │
│ normal at screening                                │ of normal at screening                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History or other evidence of bleeding from         │ History or other evidence of bleeding from         │
│ esophageal varices or other conditions consistent  │ esophageal varices or other conditions consistent  │
│ with decompensated liver disease                   │ with decompensated liver disease                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History or other evidence of a medical condition   │ History or other evidence of a medical condition   │
│ associated with chronic liver disease other than   │ associated with chronic liver disease other than   │
│ HBV (e g hemochromatosis autoimmune hepatitis      │ HBV (e g hemochromatosis autoimmune hepatitis      │
│ metabolic liver diseases including Wilson's and    │ metabolic liver diseases including Wilson's and    │
│ alpha1-antitrypsin deficiency alcoholic liver      │ alpha1-antitrypsin deficiency alcoholic liver      │
│ disease toxin exposures thalassemia)               │ disease toxin exposures thalassemia)               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women with ongoing pregnancy or who are breast     │ Women with ongoing pregnancy or who are breast     │
│ feeding                                            │ feeding                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Neutrophil count <1500 cells/mm3 or platelet count │ Neutrophil count \<1500 cells/mm3 or platelet      │
│ <90 000 cells/mm3 at screening                     │ count \<90 000 cells/mm3 at screening              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hemoglobin < 11 5 g/dL for females and < 12 5 g/dL │ Hemoglobin \< 11 5 g/dL for females and \< 12 5    │
│ for men at screening                               │ g/dL for men at screening                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum creatinine level >120 umol/ml for men and    │ Serum creatinine level \>120 umol/ml for men and   │
│ >105 umol/ml for women at screening                │ \>105 umol/ml for women at screening               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of severe psychiatric disease especially   │ History of severe psychiatric disease especially   │
│ depression Severe psychiatric disease is defined   │ depression Severe psychiatric disease is defined   │
│ as major depression or psychosis a period of       │ as major depression or psychosis a period of       │
│ treatment with an antidepressant medication or     │ treatment with an antidepressant medication or     │
│ major tranquilizer at therapeutic doses for        │ major tranquilizer at therapeutic doses for        │
│ depression or psychosis for at least 3 months a    │ depression or psychosis for at least 3 months a    │
│ suicidal attempt hospitalization for psychiatric   │ suicidal attempt hospitalization for psychiatric   │
│ disease or a period of disability due to a         │ disease or a period of disability due to a         │
│ psychiatric disease                                │ psychiatric disease                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of immunologically mediated disease (e g   │ History of immunologically mediated disease (e g   │
│ inflammatory bowel disease idiopathic              │ inflammatory bowel disease idiopathic              │
│ thrombocytopenic purpura lupus erythematosus       │ thrombocytopenic purpura lupus erythematosus       │
│ autoimmune hemolytic anemia scleroderma severe     │ autoimmune hemolytic anemia scleroderma severe     │
│ psoriasis rheumatoid arthritis)                    │ psoriasis rheumatoid arthritis)                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History or other evidence of chronic pulmonary     │ History or other evidence of chronic pulmonary     │
│ disease associated with functional limitation      │ disease associated with functional limitation      │
│ Severe cardiac disease (e g NYHA Functional Class  │ Severe cardiac disease (e g NYHA Functional Class  │
│ III or IV myocardial infarction within 6 months    │ III or IV myocardial infarction within 6 months    │
│ ventricular tachyarrhythmias requiring ongoing     │ ventricular tachyarrhythmias requiring ongoing     │
│ treatment unstable angina or other significant     │ treatment unstable angina or other significant     │
│ cardiovascular diseases)                           │ cardiovascular diseases)                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of a severe seizure disorder or current    │ History of a severe seizure disorder or current    │
│ anticonvulsant use                                 │ anticonvulsant use                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Evidence of an active or suspected cancer or a     │ Evidence of an active or suspected cancer or a     │
│ history of malignancy where the risk of recurrence │ history of malignancy where the risk of recurrence │
│ is >=20% within 2 years Patients with a lesion     │ is \>=20% within 2 years Patients with a lesion    │
│ suspicious of hepatic malignancy on a screening    │ suspicious of hepatic malignancy on a screening    │
│ imaging study will only be eligible if the         │ imaging study will only be eligible if the         │
│ likelihood of carcinoma is <=10% following an      │ likelihood of carcinoma is \<=10% following an     │
│ appropriate evaluation                             │ appropriate evaluation                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of having received any systemic anti-      │ History of having received any systemic anti-      │
│ neoplastic (including radiation) or                │ neoplastic (including radiation) or                │
│ immunomodulatory treatment (including systemic     │ immunomodulatory treatment (including systemic     │
│ corticosteroids) <=6 months prior to the first     │ corticosteroids) \<=6 months prior to the first    │
│ dose of study drug or the expectation that such    │ dose of study drug or the expectation that such    │
│ treatment will be needed at any time during the    │ treatment will be needed at any time during the    │
│ study                                              │ study                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Major organ transplantation                        │ Major organ transplantation                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Thyroid disease with thyroid function poorly       │ Thyroid disease with thyroid function poorly       │
│ controlled on prescribed medications Patients with │ controlled on prescribed medications Patients with │
│ abnormal thyroid stimulating hormone or T4         │ abnormal thyroid stimulating hormone or T4         │
│ concentrations with elevation of antibodies to     │ concentrations with elevation of antibodies to     │
│ thyroid peroxidase and any clinical manifestations │ thyroid peroxidase and any clinical manifestations │
│ of thyroid disease are excluded                    │ of thyroid disease are excluded                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History or other evidence of severe retinopathy (e │ History or other evidence of severe retinopathy (e │
│ g CMV retinitis macula degeneration) or clinically │ g CMV retinitis macula degeneration) or clinically │
│ relevant ophthalmological disorder due to diabetes │ relevant ophthalmological disorder due to diabetes │
│ mellitus or hypertension                           │ mellitus or hypertension                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Inability or unwillingness to provide informed     │ Inability or unwillingness to provide informed     │
│ consent or abide by the requirements of the study  │ consent or abide by the requirements of the study  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History or other evidence of severe illness or any │ History or other evidence of severe illness or any │
│ other conditions which would make the patient in   │ other conditions which would make the patient in   │
│ the opinion of the investigator unsuitable for the │ the opinion of the investigator unsuitable for the │
│ study                                              │ study                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with a value of alpha-fetoprotein >100    │ Patients with a value of alpha-fetoprotein \>100   │
│ ng/mL are excluded unless stability (less than 10% │ ng/mL are excluded unless stability (less than 10% │
│ increase) has been documented over at least the    │ increase) has been documented over at least the    │
│ previous 3 months                                  │ previous 3 months                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Evidence of drug and/or alcohol abuse (20g/day for │ Evidence of drug and/or alcohol abuse (20g/day for │
│ women & 30g/day for men)                           │ women \& 30g/day for men)                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients included in another trial or having been  │ Patients included in another trial or having been  │
│ given investigational drugs within 12 weeks prior  │ given investigational drugs within 12 weeks prior  │
│ to screening                                       │ to screening                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any known history of hypersensitivity to           │ Any known history of hypersensitivity to           │
│ interferon                                         │ interferon                                         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have maximum age of 70 Years │
├───────────────────────────────────┤
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛